Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature
ABSTRACT SMARCA4‐deficient undifferentiated tumor (SMARCA4‐UT) in the chest is a high‐grade malignant tumor that grows rapidly and often carries a poor prognosis. Unfortunately, there are currently no effective treatment available until now. Here, we report a case of SMARCA4‐UT in a patient who show...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | The Clinical Respiratory Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/crj.70036 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846108058597457920 |
|---|---|
| author | Yuanhang Wang Kelei Zhao Jingjing Zhang Xiaohan Yuan Yanting Liu Jinghang Zhang Ping Lu Min Zhang |
| author_facet | Yuanhang Wang Kelei Zhao Jingjing Zhang Xiaohan Yuan Yanting Liu Jinghang Zhang Ping Lu Min Zhang |
| author_sort | Yuanhang Wang |
| collection | DOAJ |
| description | ABSTRACT SMARCA4‐deficient undifferentiated tumor (SMARCA4‐UT) in the chest is a high‐grade malignant tumor that grows rapidly and often carries a poor prognosis. Unfortunately, there are currently no effective treatment available until now. Here, we report a case of SMARCA4‐UT in a patient who showed a swift response to a combination treatment of penpulimab, anlotinib, and chemotherapy. A 55‐year‐old man was diagnosed with thoracic SMARCA4‐UT along with metastases to multiple lymph nodes, the pleura, and bones. Immunohistochemical (IHC) testing indicated the absence of PD‐L1 expression in tumor cells. He was given sintilimab and anlotinib as first line treatment. However, a follow‐up chest CT revealed progressive disease (PD) after the first cycle treatment. Subsequently, the second line regimen was modified to etoposide and cisplatin (EP) combined with anlotinib and penpulimab. The effectiveness evaluation revealed partial remission (PR) following two cycles of the second‐line regimen treatment. Notably, the patient's progress‐free survival (PFS) exceeds 7 months and the overall survival up to 12 months. Our case implies that a combination of chemotherapy, anlotinib, and penpulimab might offer a promising therapeutic approach for PD‐L1‐negative thoracic SMARCA4‐UT. |
| format | Article |
| id | doaj-art-374f6ac93a0148e4ab83f4f5c6d91b22 |
| institution | Kabale University |
| issn | 1752-6981 1752-699X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Clinical Respiratory Journal |
| spelling | doaj-art-374f6ac93a0148e4ab83f4f5c6d91b222024-12-26T04:22:37ZengWileyThe Clinical Respiratory Journal1752-69811752-699X2024-12-011812n/an/a10.1111/crj.70036Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of LiteratureYuanhang Wang0Kelei Zhao1Jingjing Zhang2Xiaohan Yuan3Yanting Liu4Jinghang Zhang5Ping Lu6Min Zhang7Department of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui ChinaDepartment of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui ChinaDepartment of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui ChinaDepartment of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui ChinaDepartment of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui ChinaDepartment of Pathology The First Affiliated Hospital of Xinxiang Medical University Weihui ChinaDepartment of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui ChinaDepartment of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui ChinaABSTRACT SMARCA4‐deficient undifferentiated tumor (SMARCA4‐UT) in the chest is a high‐grade malignant tumor that grows rapidly and often carries a poor prognosis. Unfortunately, there are currently no effective treatment available until now. Here, we report a case of SMARCA4‐UT in a patient who showed a swift response to a combination treatment of penpulimab, anlotinib, and chemotherapy. A 55‐year‐old man was diagnosed with thoracic SMARCA4‐UT along with metastases to multiple lymph nodes, the pleura, and bones. Immunohistochemical (IHC) testing indicated the absence of PD‐L1 expression in tumor cells. He was given sintilimab and anlotinib as first line treatment. However, a follow‐up chest CT revealed progressive disease (PD) after the first cycle treatment. Subsequently, the second line regimen was modified to etoposide and cisplatin (EP) combined with anlotinib and penpulimab. The effectiveness evaluation revealed partial remission (PR) following two cycles of the second‐line regimen treatment. Notably, the patient's progress‐free survival (PFS) exceeds 7 months and the overall survival up to 12 months. Our case implies that a combination of chemotherapy, anlotinib, and penpulimab might offer a promising therapeutic approach for PD‐L1‐negative thoracic SMARCA4‐UT.https://doi.org/10.1111/crj.70036anlotinibimmune checkpoint inhibitorsthoracic SMARCA4‐deficient undifferentiated tumor |
| spellingShingle | Yuanhang Wang Kelei Zhao Jingjing Zhang Xiaohan Yuan Yanting Liu Jinghang Zhang Ping Lu Min Zhang Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature The Clinical Respiratory Journal anlotinib immune checkpoint inhibitors thoracic SMARCA4‐deficient undifferentiated tumor |
| title | Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature |
| title_full | Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature |
| title_fullStr | Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature |
| title_full_unstemmed | Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature |
| title_short | Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature |
| title_sort | rapid response to penpulimab combined with anlotinib and chemotherapy in a thoracic smarca4 ut without pd l1 expression a case report and review of literature |
| topic | anlotinib immune checkpoint inhibitors thoracic SMARCA4‐deficient undifferentiated tumor |
| url | https://doi.org/10.1111/crj.70036 |
| work_keys_str_mv | AT yuanhangwang rapidresponsetopenpulimabcombinedwithanlotinibandchemotherapyinathoracicsmarca4utwithoutpdl1expressionacasereportandreviewofliterature AT keleizhao rapidresponsetopenpulimabcombinedwithanlotinibandchemotherapyinathoracicsmarca4utwithoutpdl1expressionacasereportandreviewofliterature AT jingjingzhang rapidresponsetopenpulimabcombinedwithanlotinibandchemotherapyinathoracicsmarca4utwithoutpdl1expressionacasereportandreviewofliterature AT xiaohanyuan rapidresponsetopenpulimabcombinedwithanlotinibandchemotherapyinathoracicsmarca4utwithoutpdl1expressionacasereportandreviewofliterature AT yantingliu rapidresponsetopenpulimabcombinedwithanlotinibandchemotherapyinathoracicsmarca4utwithoutpdl1expressionacasereportandreviewofliterature AT jinghangzhang rapidresponsetopenpulimabcombinedwithanlotinibandchemotherapyinathoracicsmarca4utwithoutpdl1expressionacasereportandreviewofliterature AT pinglu rapidresponsetopenpulimabcombinedwithanlotinibandchemotherapyinathoracicsmarca4utwithoutpdl1expressionacasereportandreviewofliterature AT minzhang rapidresponsetopenpulimabcombinedwithanlotinibandchemotherapyinathoracicsmarca4utwithoutpdl1expressionacasereportandreviewofliterature |